Lentine K, Schnitzler M, Brennan D, et al.
Does Cardiac Evaluation Delay Kidney Transplantation in Lower Risk
Dialysis Patients?
ASN Annual Meeting -- San Francisco
J Am Soc Nephrol
(Nov) 18:712A 2007

Recent studies challenge the value of invasive interventions for stable
coronary artery disease in the general population. Among kidney transplant
(KTX) candidates, effectiveness of cardiac screening is controversial. We
retrospectively investigated associations of cardiac evaluations (CE) with
time to KTX and mortality among dialysis patients.
We examined US
Renal Data System records for patients who achieved access to the deceased
donor wait list or live donor transplant in 1991-2002, received Medicare-
insured dialysis for > 6mo and maintained Medicare through KTX
access. Patients were stratified as
high
risk
(age > 50, diabetes or known
cardiovascular disease; n=10,835) vs
lower
risk
(n=6,673) at ESRD onset. CE were defined
by billing claims for coronary angiography, stress echocardiography,
myocardial perfusion study or exercise treadmill submitted between 1st ESRD
service and earliest of listing or KTX.
Assuming decision to evaluate
for KTX as a baseline factor at ESRD, incidence of KTX did not vary by CE
status in high risk patients. However, times to live donor and total KTX were
longer in lower risk patients who underwent CE. Survival was also inferior in
lower risk patients who received CE.

Association of CE with increased mortality in the lower risk
group persisted in multivariable regression and with case-matching for
predicted probability of CE.
Among dialysis patients at lower baseline
risk according to criteria commonly used in screening decisions, time to KTXs
were longer in those who underwent CE. While these associations cannot prove
causation, the data support need for prospective evaluation pre-KTX cardiac
screening practices in relation to timeliness of KTX access in lower risk
patients.

© Copyright 2007-2008, American Society of Nephrology.
Reproduced with permission.
Until September of 2008, all ASN abstracts
from the 2007 Annual Meeting are available at this link.
Disclaimer: Abstracts often have errors, both
typographical and otherwise. This posting is an electronic translation of
submitted abstracts which has not been verified against the original
submitted abstract nor with the authors for accuracy. As a result, there
may be errors, especially with regard to drug doses, but not limited to
these. Abstracts undergo only limited review, and data often are changed
as a result of the peer review process, so their reliability is less than
manuscripts published in peer-reviewed journals. In using these
summaries, you are agreeing that you are aware of these limitations.
The materials are provided on an as-is basis without any warranty of
any kind, either express or implied. In addition to errors, the
information presented may be incomplete or outdated.
The information contained is not intended nor recommended as a substitute
for professional medical advice. You are advised to check the appropriate
medical literature and the product information currently provided by the
manufacturer of each device to be used or drug to be administered to
verify the dosage, the method and duration of administration, or
contraindications. It is the responsibility of the treating physician or
other health care professional, relying on independent experience and
knowledge of the patient, to determine drug, disease, and the best
treatment for the patient.
To the fullest extent permitted by law, HDCN, ASN and their affiliates and
suppliers disclaim all
warranties, express or implied, including, but not limited to, any
warranty of merchantability, non- infringement or fitness for a
particular purpose.
In no event shall HDCN, ASN, or their affiliates or suppliers be
liable for any damages whatsoever (including, but not limited to,
direct, indirect, incidental, consequential, punitive or exemplary
damages, or any damages for loss of profits, use, data, goodwill or
other intangibles) arising from or in any way relating to these terms,
the materials, or any information, goods or services obtained from or
referred to in the materials, whether based on warranty, contract, tort
(including, but not limited to, negligence), or any other legal theory,
and whether or not any or all of the limited entities is advised of the
possibility of such damages.
|